Verition Fund Management’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,116
Closed -$595K 2920
2025
Q4
$595K Sell
6,116
-3,512
-36% -$301K ﹤0.01% 2534
2025
Q3
$685K Sell
9,628
-2,220
-19% -$148K ﹤0.01% 2824
2025
Q2
$708K Buy
11,848
+5,512
+87% +$302K ﹤0.01% 2717
2025
Q1
$333K Sell
6,336
-1,771
-22% -$99.5K ﹤0.01% 2818
2024
Q4
$446K Buy
+8,107
New +$427K ﹤0.01% 2550

Other funds holding IRMD

Verition Fund Management's IRMD Position: Q1 2026 in Review

Verition Fund Management sold out of iRadimed (IRMD) in Q1 2026, closing a stake of 6,116 shares — an estimated $595K sold.

Verition Fund Management first reported a position in IRMD in Q4 2024 and held it in 5 quarters. The position peaked at $708K in Q2 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Verition Fund Management reported no remaining iRadimed position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 6,116 iRadimed shares in Q1 2026, an estimated $595K.
  • Verition Fund Management first reported a position in iRadimed in Q4 2024 and held it in 5 quarters.
  • Verition Fund Management's iRadimed position peaked at $708K in Q2 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.